NCT07518173 2026-04-08A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerSichuan Baili Pharmaceutical Co., Ltd.Phase 3 Not yet recruiting596 enrolled
NCT07116824 2025-08-12HB1801 Combined Treatment of HER2-positive Breast CancerCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 2 Not yet recruiting80 enrolled